

## IVMB0235

---

**Product Information**

<b>Product SKU:</b>	IVMB0235	<b>Clone:</b>	ABT-874	<b>Target:</b>	IL-12/IL-23 p40
<b>Size:</b>	100 mg, 25 mg, 50 mg, 5.0 mg, 1.0 mg	<b>Isotype:</b>	Human IgG1 $\lambda$		

---

**Additional Information**

<b>Reactivity:</b>	Human	<b>Host Species:</b>	Human
<b>Antibody Type:</b>	Biosimilar Recombinant Human Monoclonal Antibody	<b>Expression Host:</b>	HEK-293 Cells

---

**Immunogen Information**

**Background:** Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23 $\alpha$  to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

**Endotoxin Level:** < 1.0 EU/mg as determined by the LAL method

**Applications:** B

**Synonyms:** IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23

**Antigen Distribution:** IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.

<b>Immunogen:</b>	This antibody was produced by phage display technology.
<b>Formulation:</b>	This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
<b>Specificity:</b>	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.
<b>Product Preparation:</b>	Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
<b>Storage &amp; Handling:</b>	Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.